Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
Upcoming Events
May 7, 2024
Q1 2024 Financial Results
June 26, 2024
Annual General Meeting
Contact
Investor Relations Team
Campus Bio-Ouest6, Rue Alain Bombard
44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva.com